Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy

BMC Medical Genomics

Anne-Marie Cleton-Jansen²  Pancras CW Hogendoorn²  Horst Bürger¹  Massimo Serra⁶  Emilie P Buddingh⁴  Monique Mommersteeg⁵  Riet Hilhorst⁵  Brendy EWM van den Akker²  Marieke L Kuijjer³ 

[1] Institute of Pathology, Paderborn/Höxter, Germany;Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2300RC Leiden, The Netherlands;Current affiliation: Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA;Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands;PamGene International BV, ‘s-Hertogenbosch, The Netherlands;Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

关键词: Bone tumor;    Genomic instability;    Gene expression profiling;    Kinome profiling;    Tumor cell lines;    Osteosarcoma;   

Others  :  1090988
DOI  :  10.1186/1755-8794-7-4

 received in 2013-04-24, accepted in 2014-01-14,  发布年份 2014

【 摘 要 】

Background

High-grade osteosarcoma is a primary malignant bone tumor mostly occurring in adolescents and young adults, with a second peak at middle age. Overall survival is approximately 60%, and has not significantly increased since the introduction of neoadjuvant chemotherapy in the 1970s. The genomic profile of high-grade osteosarcoma is complex and heterogeneous. Integration of different types of genome-wide data may be advantageous in extracting relevant information from the large number of aberrations detected in this tumor.

Methods

We analyzed genome-wide gene expression data of osteosarcoma cell lines and integrated these data with a kinome screen. Data were analyzed in statistical language R, using LIMMA for detection of differential expression/phosphorylation. We subsequently used Ingenuity Pathways Analysis to determine deregulated pathways in both data types.

Results

Gene set enrichment indicated that pathways important in genomic stability are highly deregulated in these tumors, with many genes showing upregulation, which could be used as a prognostic marker, and with kinases phosphorylating peptides in these pathways. Akt and AMPK signaling were identified as active and inactive, respectively. As these pathways have an opposite role on mTORC1 signaling, we set out to inhibit Akt kinases with the allosteric Akt inhibitor MK-2206. This resulted in inhibition of proliferation of osteosarcoma cell lines U-2 OS and HOS, but not of 143B, which harbors a KRAS oncogenic transformation.

Conclusions

We identified both overexpression and hyperphosphorylation in pathways playing a role in genomic stability. Kinome profiling identified active Akt signaling, which could inhibit proliferation in 2/3 osteosarcoma cell lines. Inhibition of PI3K/Akt/mTORC1 signaling may be effective in osteosarcoma, but further studies are required to determine whether this pathway is active in a substantial subgroup of this heterogeneous tumor.

【 授权许可】

   
2014 Kuijjer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Raymond AK, Ayala AG, Knuutila S: Conventional osteosarcoma. In World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:264-270.
• [2]Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution. Cancer 2006, 106:1154-1161.
• [3]Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H: Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010, 54:216-221.
• [4]Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR: A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012:704872.
• [5]Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011, 47:2431-2445.
• [6]Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M: Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010, 15:615-634.
• [7]Cleton-Jansen AM, Buerger H, Hogendoom PCW: Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol 2005, 11:390-399.
• [8]Szuhai K, Cleton-Jansen AM, Hogendoorn PC, Bovee JV: Molecular pathology and its diagnostic use in bone tumors. Cancer Genet 2012, 205:193-204.
• [9]Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Burger H, Myklebost O, Hogendoorn PCW, Meza-Zepeda LA, Cleton-Jansen AM: Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012, 51:696-706.
• [10]Lockwood WW, Stack D, Morris T, Grehan D, O’Keane C, Stewart GL, Cumiskey J, Lam WL, Squire JA, Thomas DM, O’Sullivan MJ: Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn 2011, 13:289-296.
• [11]Wachtel M, Schafer BW: Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010, 36:318-327.
• [12]Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R: R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010, 55:67-75.
• [13]Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD: Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012, 30:78-84.
• [14]Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van OJ, Taminiau AHM, van Wezel T, Hogendoorn PCW, Bovee JVMG: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009, 69:6216-6222.
• [15]Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PCW, Bovee JVMG: Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. Mol Cancer 2010, 9:257.
• [16]Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PCW, Llombart-Bosch A, Cleton-Jansen AM: Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011, 91:1195-1205.
• [17]Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010, 49:40-51.
• [18]Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn I, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AHM, Hogendoorn PCW: Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009, 101:2064.
• [19]Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA: Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011, 59:518-524.
• [20]R Development Core Team: R: A language and environment for statistical computing, reference index version 2.15.0. Vienna, Austria: R Foundation for Statistical Computing; 2011.
• [21]Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PCW, Lankester AC, Cleton-Jansen AM: Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents. Clin Cancer Res 2011, 17:2110-2119.
• [22]Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R: Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples. In Gene Regulation: Methods and Protocols, Methods in Molecular Biology. Edited by Bina M. New York: Springer Science+Business Media, LLC; 2013.
• [23]Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004., 3(3)
• [24]Huber W, Von HA, Sultmann H, Poustka A, Vingron M: Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(1):S96-S104.
• [25]Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. BioMed Central Full Text
• [26]Kauffmann A, Gentleman R, Huber W: arrayQualityMetrics–a bioconductor package for quality assessment of microarray data. Bioinformatics 2009, 25:415-416.
• [27]Mohseny AB, Cai Y, Kuijjer M, Xiao W, van den Akker B, de Andrea CE, Jacobs R, ten Dijke P, Hogendoorn PCW, Cleton-Jansen AM: The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. Eur J Cancer 2012, 48:3429-3438.
• [28]Rhim JS, Cho HY, Huebner RJ: Non-producer human cells induced by murine sarcoma virus. Int J Cancer 1975, 15:23-29.
• [29]Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043-1048.
• [30]Mohseny AB, Tieken C, van der Velden PA, Szuhai K, de AC, Hogendoorn PCW, Cleton-Jansen AM: Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer 2010, 49:1095-1103.
• [31]Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM: IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013, 13:245. BioMed Central Full Text
• [32]Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
• [33]Memmott RM, Dennis PA: Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009, 21:656-664.
• [34]Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
• [35]Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
• [36]Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
• [37]Vakana E, Altman JK, Platanias LC: Targeting AMPK in the treatment of malignancies. J Cell Biochem 2012, 113:404-409.
• [38]Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B: PhosphoSite: a bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 2004, 4:1551-1561.